Supernus: Stock Slides As Qelbree Sales Questioned, But Positives Still Outweigh Negatives

Simon Webb and Duncan Nicholls/OJO Images via Getty Images Investment Overview The last - and also the first - time I covered Supernus Pharmaceuticals (NASDAQ:SUPN) for Seeking Alpha was in November 2023. I gave the company's stock a "strong buy" rating - shares traded at $26 at the time - and at the time of writing they trade at a value of$30 - up ~15%. I own some stock in the company myself. At the end of last week, shares actually traded at $35 per share - up 35% since my note - however the market has b ...